SARS-CoV-2 Monoclonal Antibodies

SARS-CoV-2 monoclonal antibodies are a therapeutic class of laboratory-engineered proteins designed to provide passive immunity against severe acute respiratory syndrome coronavirus 2 This drug class is utilized for the treatment of mild-to-moderate COVID-19 in patients at high risk of progressing to severe disease, as well as for pre-exposure or post-exposure prophylaxis in individuals unable to mount an adequate immune response to vaccination

They primarily function by binding directly to specific epitopes on the viral surface—most notably the spike protein receptor-binding domain—thereby blocking viral attachment and entry into human host cells

They primarily function by binding directly to specific epitopes on the viral surface—most notably the spike protein receptor-binding domain—thereby blocking viral attachment and entry into human host cells

This drug class is utilized for the treatment of mild-to-moderate COVID-19 in patients at high risk of progressing to severe disease, as well as for pre-exposure or post-exposure prophylaxis in individuals unable to mount an adequate immune response to vaccination

This drug class is utilized for the treatment of mild-to-moderate COVID-19 in patients at high risk of progressing to severe disease, as well as for pre-exposure or post-exposure prophylaxis in individuals unable to mount an adequate immune response to vaccination

Clinical utility within this class varies substantially based on the circulating viral variant and corresponding neutralizing susceptibility

Clinical utility within this class varies substantially based on the circulating viral variant and corresponding neutralizing susceptibility